Saturday | 30 August, 2008
Medical Therapies buys midkine IP
Medical Therapies concludes purchase of midkine protein IP
Additional Resources
Newsletter Subscription
Sydney pharma Medical Therapies [ASX: MTY] has completed the purchase of the IP surrounding midkine protein-related technology assets from Japanese company Cell Signals Inc after receiving shareholder approval.
Cell Signals today traded all midkine protein-related IP rights to Medical Therapies, in exchange for 20 million shares of Medical Therapies stock.
These include patents, trademarks, manufacturing information and technical know-how, on top of all Cell Signals' stocks of midkine protein and reagents.
The agreement was announced in April. Midkine is a neurite growth promoting factor, active in oncogenesis and inflammation.
Australian Life Scientist Member Login
Beyond The Hybrid TV Card Norm 2008-08-26 15:29:00+10
Go Green with Kingston - Save the PCB, Save the World 2008-08-25 16:10:00+10
VIA Pico-ITX at the Heart of Modern Robots 2008-08-25 13:50:00+10
Fujitsu unveils winning formula for success with Intel® Centrino® 2 processor technology. 2008-08-25 12:42:00+10
Multimedia Technology & Herma Technologies announce new audience feedback solution from REPLY Systems. 2008-08-19 11:05:00+10
Sponsored Links
Subscribe to Australian Life Scientist
Australian Life Scientist is Australia's leading magazine for the life sciences sector. ALS is available free of charge to qualified persons working in the life sciences - register now for your free subscription.
